SonoMotion is developing a non-invasive medical device platform that utilizes low-pressure ultrasound waves to fragment and reposition kidney stones in awake patients, eliminating the need for general anesthesia and x-ray radiation. This approach addresses the high volume of kidney stone procedures by providing a safer, cost-effective treatment option that can be performed in an office setting.
Funding
$12.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AMLRFounders
Product
Problem
Current methods for treating kidney stones often require general anesthesia and X-ray radiation, leading to increased risks and costs for patients. These procedures are typically performed in a hospital setting, limiting accessibility and convenience.
Solution
SonoMotion is developing a non-invasive platform that utilizes low-pressure ultrasound waves to fragment and reposition kidney stones in fully awake patients. The platform consists of two products: Break Wave™ and Stone Clear™. Break Wave™ therapy is designed to fragment kidney stones into small pieces, while Stone Clear™ therapy repositions post-lithotripsy residual fragments to facilitate natural passage. Both therapies can be administered in an office setting with minimal to no anesthesia, reducing the need for hospital visits and improving patient comfort.
Target Audience
The primary target audience includes urologists and other medical professionals who treat kidney stone disease, as well as patients seeking less invasive and more convenient treatment options.
Features
- Break Wave™: Uses low-pressure ultrasound to fragment kidney stones.
- Stone Clear™: Repositions kidney stone fragments post-lithotripsy.
- Non-invasive procedure performed on fully awake patients.
- Office-based treatment, reducing the need for hospitalization.
- Reduced or eliminated need for general anesthesia.
- Reduced or eliminated need for X-ray radiation.